Business
Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
LAVAL, QC, Feb. 11 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announces today that on...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nLAVAL, QC, Feb. 11 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM)\nannounces today that on Wednesday, February 13, 2008, Dr. Francesco Bellini,\nNeurochem's Chairman, President and Chief Executive Officer, and Mr. Gary\nSchmid, Chief Executive Officer of the new nutraceutical business, will\npresent Neurochem's strategy at the 2008 BIO CEO & Investor Conference to be\nheld at the Waldorf-Astoria, in New York (NY). The presentation will take\nplace at 11:00 A.M. EST, in the West Foyer room.\n\n\nThe live Web cast of Neurochem's presentation (audio and visual) can be\naccessed at\nhttp://www.corporate-ir.net/ireye/conflobby.zhtml?ticker(equal sign)NRMX&item_id(equal sign)17. A\nreplay of the presentation will begin one (1) hour after the actual\npresentation time, and will be available until February 20, 2008. Please\naccess the Web cast approximately 15 minutes before the presentation is\nscheduled to begin.\n\n\nAbout Neurochem\n\n\nNeurochem Inc. is a global health company focused on the research,\ndevelopment and commercialization of products to provide innovative health\nsolutions to address critical unmet medical needs.\n\n\nTo Contact Neurochem\n\n\nFor additional information on Neurochem and its drug development\nprograms, please call the North American toll-free number 1-877-680-4500 or\nvisit our Web Site at www.neurochem.com.\n\n\nCertain statements contained in this news release, other than statements\nof fact that are independently verifiable at the date hereof, may constitute\nforward-looking statements. Such statements, based as they are on the current\nexpectations of management, inherently involve numerous risks and\nuncertainties, known and unknown, many of which are beyond Neurochem Inc.'s\ncontrol. Such risks include but are not limited to: the impact of general\neconomic conditions, general conditions in the pharmaceutical and/or\nnutraceutical industry, changes in the regulatory environment in the\njurisdictions in which the Neurochem group does business, stock market\nvolatility, fluctuations in costs, and changes to the competitive environment\ndue to consolidation, that actual results may vary once the final and\nquality-controlled verification of data and analyses has been completed, as\nwell as other risks disclosed in public filings of Neurochem Inc.\nConsequently, actual future ...